What is holding back apomorphine therapy for Parkinson’s disease? Identifying knowledge gaps amongst Thai neurological medical professionals
Objective: To assess the level of understanding about, and identify knowledge gaps in, apomorphine therapy amongst Thai neurological medical professionals. Background: Continuous subcutaneous apomorphine infusion…The Indian Experience of Continuous Dopaminergic therapy with Apomorphine in Parkinson’s Disease
Objective: A clinical audit of apomorphine pumps – The Indian experience. Background: Continuous dopaminergic therapy remains crucial in the management of moderately advanced Parkinson’s disease…Palliative care and Parkinson’s disease: current practice, knowledge and barriers to referral; Insights from palliative care units in Brittany, France
Objective: To assess the current practice regarding patients with Parkinson’s disease (PD) in palliative care units and to identify barriers to patients’ referral and optimal…Apomorphine subcutaneous infusion reduces dopaminergic dosage whilst maintaining motor benefits in Parkinson’s disease: A prospective analysis of Thai Apomorphine Registry
Objective: To evaluate a reduction of LED in PD patients who achieve satisfactory motor control with long-term continuous subcutaneous apomorphine infusion (CSAI) Background: Apomorphine is…Apomorphine improves pulmonary function in parkinsonian patients
Objective: Aim of the study; to investigate if apomorphine might facilitate weaning from mechanical ventilation in parkinsonian patients. Background: Apomorphine is an effective treatment for PD…Management of parkinsonian patients with long-term DBS and incomplete control of symptoms
Objective: We want to evaluate if apomorphine infusions can improve symptom control in PD patients with long standing DBS and functional decline. Background: Deep brain stimulation…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting
Objective: Analyze effect of concomitant antiemetics and dopamine agonists (DA) on nausea and vomiting (N/V) in patients receiving apomorphine sublingual film (APL-130277; APL) for on-demand…A monocentric experience of Apomorphine pump follow-up on PD patients: The Optipump Cohort
Objective: The goal of this study is to describe the factors that may have an impact on Continuous Subcutaneous Apomorphine Infusion (CSAI) therapy initiation and…Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact on Impulse Control Disorders
Objective: Evaluate effect of apomorphine sublingual film (APL-130277; APL) on impulse control disorders (ICD) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In…Apomorphine as a Diagnostic tool to Identify Levodopa Responsive Atypical Parkinsonism
Objective: To assess the efficacy of apomorphine in identification of levodopa responsive atypical parkinsonism. Background: Management of atypical parkinsonism is a challenge. Most of these…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 12
- Next Page »